Shire adds to gastrointestinal portfolio with Pfizer compound acquisition
Shire (LSE: SHP) has announced that it has acquired an investigational biologic for the treatment inflammatory bowel disease from Pfizer (NYSE: PFE).
PF-00547659 is a fully-human monoclonal antibody that is designed to directly target a gastrointestinal endothelial adhesion molecule that binds to the α4β7 integrin on lymphocytes. The biologic is set to begin Phase III trials after meeting its primary and secondary endpoint in Phase II trials.
The drug is expected to treat chronic conditions such as ulcerative colitis and Crohn’s disease. The prevalence of the various forms of inflammatory bowel disease (IBD) are estimated to affect more than 3.5 million people in the US, EU and Japan.
Howard Mayer, head of clinical development at Shire, says: “This licensing transaction fits with Shire’s commitment to advancing research and development in select speciality areas, including areas of unmet patient need for gastrointestinal conditions such as IBD. We look forward to continuing the development of PF-00547659, a unique and differentiated biologic that will benefit from our experience in IBD and across the gastrointestinal space.”
Freeline Therapeutics has announced that it has entered into a definitive agreement with newly established …
Merck (known as MSD outside of the US and Canada) and Caraway Therapeutics have announced …